Investing.com -- Shares of Nanexa surged more than 110% in early Friday trading after the Swedish drug-delivery company announced a global licensing and collaboration agreement with Novo Nordisk worth up to €1.165 billion ($1.3 billion), covering technology aimed at making obesity and diabetes treatments longer-lasting. Still guessing which names to buy? Our AI rebuilds its stock picks at the start of every month. The list is beating the market by 120%. See what's on it » Under the deal, Novo Nordisk secures an exclusive worldwide license to Nanexa's PharmaShell platform, an atomic layer deposition-based drug delivery technology, for use in up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.